A phase 2 trial for the treatment of hidradenitis suppurativa has begun with the dosing of the first patient with AVTX-009. The trial is being conducted by Avalo Therapeutics and is expected to have topline results in 2026. AVTX-009 is a humanized monoclonal antibody that binds to interleukin-1 beta to neutralize its activity. The trial will involve approximately 180 adults with moderate to severe HS who will be randomly assigned to receive AVTX-009 or a placebo. The primary efficacy endpoint is the proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 by the end of the study. Secondary endpoints include disease severity scores, inflammatory nodule counts, and skin pain reports.
Source link
First patient dosed in phase 2 trial evaluating AVTX-009 for hidradenitis suppurativa
